Oct 03, 2019 / 08:30PM GMT
Li Chen - Thermo Fisher Scientific Inc. - VP of Gene Synthesis and Mol Bio LCS
Good afternoon. Can you hear me? Okay. Good afternoon. Welcome to the CGT China panel. And my name is Li Chen. I'm very pleased to be here today. I'm the VP of Gene Synthesis and Mol Bio LCS at Thermo Fisher Scientific.
So we are all inspired by the recent advances in cell and gene therapy and the integration of the novel technologies in cell and gene therapy really inspired us. This includes the CRISPR edited cell therapy, the induced pluripotent stem cell integrated into the next-gen therapy and also the mRNA therapeutics. There's so many great things happening out there in China. And this is why today we are very happy to have Felix and Yuling here. And there are more targets to be explored, more clinical trials and more patients being enrolled in trials. And in terms of pipeline, definitely U.S. and China are holding the leading position in terms of pipeline. And I'm thrilled to join the China market leaders here for the next 30 minutes to share with you about the China cell and gene therapy.
So Felix and
Thermo Fisher Scientific Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa Transcript
Oct 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers